Cadrenal Therapeutics第二季度每股收益$（1.87）错过$（1.60）估计

Cadrenal Therapeutics (NASDAQ: CVKD) reported quarterly losses of $(1.87) per share which missed the analyst consensus estimate of $(1.60) by 17.09 percent. This is a 16.89 percent increase over losses of $(2.25) per share from the same period last year.